Charles Schwab Investment Management Inc Vaxcyte, Inc. Transaction History

Charles Schwab Investment Management Inc

$521 Billion
Q1 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,333,382 shares of PCVX stock, worth $47.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,333,382

Previous 1,341,773 0.63%

Holding current value

$47.8 Million

Previous $110 Million 54.16%

% of portfolio

0.01%

Previous 0.02%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	SELL	$37.76 - $92.13 $316,844 - $773,062	-8,391 Reduced 0.63%	1,333,382 $50.3 Million
Q4 2024 Feb 06, 2025	BUY	$80.97 - $117.93 $3.72 Million - $5.42 Million	45,936 Added 3.54%	1,341,773 $110 Million
Q3 2024 Nov 12, 2024	BUY	$70.52 - $117.12 $29.6 Million - $49.1 Million	419,600 Added 47.89%	1,295,837 $148 Million
Q2 2024 Aug 12, 2024	BUY	$60.06 - $78.77 $2.56 Million - $3.36 Million	42,619 Added 5.11%	876,237 $66.2 Million
Q1 2024 May 08, 2024	BUY	$59.79 - $81.05 $6.17 Million - $8.36 Million	103,180 Added 14.13%	833,618 $56.9 Million
Q4 2023 Feb 06, 2024	BUY	$45.35 - $63.41 $796,799 - $1.11 Million	17,570 Added 2.46%	730,438 $45.9 Million
Q3 2023 Nov 08, 2023	BUY	$46.0 - $53.1 $4.8 Million - $5.54 Million	104,398 Added 17.16%	712,868 $36.3 Million
Q2 2023 Aug 09, 2023	BUY	$34.66 - $54.07 $4.19 Million - $6.53 Million	120,837 Added 24.78%	608,470 $30.4 Million
Q1 2023 May 11, 2023	SELL	$36.27 - $47.2 $30,684 - $39,931	-846 Reduced 0.17%	487,633 $18.3 Million
Q4 2022 Feb 13, 2023	BUY	$20.58 - $47.95 $2.95 Million - $6.87 Million	143,253 Added 41.5%	488,479 $23.4 Million
Q3 2022 Nov 14, 2022	BUY	$21.69 - $28.53 $1.21 Million - $1.59 Million	55,579 Added 19.19%	345,226 $8.29 Million
Q2 2022 Aug 15, 2022	BUY	$17.68 - $26.58 $483,654 - $727,122	27,356 Added 10.43%	289,647 $6.3 Million
Q1 2022 May 13, 2022	BUY	$17.46 - $26.36 $348,711 - $526,461	19,972 Added 8.24%	262,291 $6.34 Million
Q4 2021 Feb 11, 2022	BUY	$19.32 - $26.45 $88,311 - $120,902	4,571 Added 1.92%	242,319 $5.77 Million
Q3 2021 Nov 16, 2021	BUY	$20.26 - $26.97 $1.32 Million - $1.76 Million	65,145 Added 37.74%	237,748 $6.03 Million
Q2 2021 Aug 16, 2021	BUY	$16.45 - $24.06 $599,191 - $876,385	36,425 Added 26.75%	172,603 $3.89 Million
Q1 2021 May 17, 2021	BUY	$18.66 - $29.16 $346,796 - $541,938	18,585 Added 15.8%	136,178 $2.69 Million
Q4 2020 Feb 16, 2021	BUY	$26.57 - $51.74 $40,598 - $79,058	1,528 Added 1.32%	117,593 $3.13 Million
Q3 2020 Nov 13, 2020	BUY	$26.5 - $55.4 $3.08 Million - $6.43 Million	116,065 New	116,065 $5.73 Million

Others Institutions Holding PCVX

# of Institutions

338

Shares Held

136M

Call Options Held

348K

Put Options Held

250K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $2.13B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Vaxcyte, Inc. Transaction History